Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
Is molecular imaging the best way to determine response to treatment?
Suzanne Louise Topalian
Trial of durvalumab for bladder cancer
Is there a use for capecitabine in recurrent cervical cancer?
Quality of life and symptom control for non-squamous NSCLC patients on nivolumab (CheckMate 057)